GlanHealth™ unveils its custom marketing capabilities with private labeling of eco-friendly skin and surface sanitizing products
SAN DIEGO, CA – January 6, 2021 – Dalrada Financial Corp. (OTCQB: DFCO, “Dalrada”) is pleased to announce the launch of Dalrada Health Products’ GlanHealth™ private labeling (“white label”) marketing program for its eco-friendly, alcohol-free, non-toxic product line that incorporates quaternary ammonium compounds.
Fawad Nisar, Chief Operating Officer of Dalrada Financial Corporation, states, “GlanHealth’s ability to provide a custom labeling solution for its distribution partners provides a pathway to expanding and expediting access to safe, premium-quality personal and surface sanitizing products for institutions, businesses, and consumers worldwide.”
Providing a custom labeling program for personal and professional sanitizing products is a significant achievement with expressing GlanHealth’s ability to:
• Prove that eco-friendly, alcohol-free, non-toxic sanitizing products are trending during the global health crisis
• Provide safe, effective alternatives to traditional sanitizing modalities (bleach, chlorine, alcohol)
• Clearly show the Company’s impact with global education of institutions, businesses, and consumers through evidence-based scientific knowledge, focused communications, marketing, and sales distribution
• Share the Company’s and its distribution partners’ creation of a safer pathway to restoring normalcy through scaled manufacturing, design, and packaging capabilities
The Company’s first private label branding opportunity started with a $10,000 order of hand sanitizers. Since that time, GlanHealth™ has secured a long-term partnership with Premium PPE, a company spearheaded by Jason Armstrong and Derrick Landri, with the first order exceeding $150,000.
Co-Founder of Premium PPE, Jason Armstrong, states, “We are about bringing great people together to create a safer tomorrow!”
Premium PPE holds an extensive healthcare client-base providing a wide variety of personal protection equipment throughout Ohio, Florida, Washington, California, West Virginia, New Jersey, and New York.
Nisar concludes, “GlanHealth’s white label distribution partnership with Premium PPE is a testament of Dalrada’s continued focus on quality manufacturing, impeccable customer service, and on-time delivery with the entire product line. We look forward to adding value to Premium PPE’s extensive product portfolio as an end-to-end safety solution for the healthcare industry.”
For consumer and commercial use, GlanHealth™ provides long-lasting sanitizing solutions from skin to surface. The GlanHealth™ product suite is laboratory tested with 99.9% effectiveness (a coronavirus surrogate was used in the study). All of GlanHealth™ products are in compliance with FDA regulations for product labeling.
Shielding from microbes for up to 4-hours on skin and on surfaces for up to 28-days, GlanHealth’s revolutionary mode of action incorporates quaternary ammonium compounds that have been used in sanitizing for nearly 90-years.
GlanHealth™ safely protects all non-porous and porous surfaces including textiles, metals, plastics, and rubber. Anti-static, GlanHealth’s formulations are safe to use on electronics. Industry-specific formulations for aviation, healthcare, food preparation, and industrial applications are available.
GlanHealth’s product suite includes:
• Hand Sanitizer Foam, Wipes and Spray
• Advanced Sanitizing Soap
• All Purpose Advanced Surface Cleaner
• Antimicrobial Wound & Skin Therapy
• Mold and Mildew Sanitizing & Prevention
• Laundry Sanitizing & Deodorant
• Industrial & Commercial Surface Sanitizer (EPA product)
For additional details, visit https://DalradaHealth.com and https://GlanHealth.com
About Premium PPE
Premium PPE is committed. Protecting healthcare professionals, civil workers, and the public on a global scale is the Company’s mission. Premium PPE works alongside some of the world’s leading professionals in the medical industry. The Company’s caring commitment to quality differentiates Premium PPE from all other suppliers of personal protection equipment. Each product provided by Premium PPE undergoes rigorous inspections keeping quality a top priority. Premium PPE ensures customer satisfaction with responsiveness and accuracy that is required to advance the overall quality of healthcare. For details, visit https://premiumppe.com
About Dalrada Health Products
A subsidiary of Dalrada Financial Corp., Dalrada Health Products is focused on solving health problems around the world. The company develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. With operations in the U.S., Malaysia, and India, Dalrada Health Products can reach underserved markets through strong partnerships and the development of efficient supply chains. Dalrada Health Products is committed to solving universal health problems through improved methodologies resulting in products and services that benefit the global marketplace. For details, visit www.dalradahealth.com. For information on GlanHealth™ visit www.glanhealth.com.
About Dalrada (DFCO)
Dalrada Financial Corp. (OTCQB: DFCO, “Dalrada”) solves real-world problems by producing innovation-focused and technologically centered solutions on a global scale. Delivering next-generation manufacturing, engineering, and healthcare products and services designed to propel growth, Dalrada is a team of industry experts and an organization built upon a strong foundation of financial capital. The Company and its subsidiaries are positioned for stable long-term growth through intelligent market research, sound business acumen, and established operational infrastructure. For more information, visit http://18.104.22.168/~dalradadev2022 or call 1-858-283-1253.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the U.S. Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.
# # #